Aprea Therapeutics, Inc. (APRE)
| Market Cap | 9.78M |
| Revenue (ttm) | 123,296 |
| Net Income (ttm) | -11.95M |
| Shares Out | 12.38M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,532 |
| Open | 0.755 |
| Previous Close | 0.790 |
| Day's Range | 0.722 - 0.790 |
| 52-Week Range | 0.548 - 2.220 |
| Beta | 1.56 |
| Analysts | Strong Buy |
| Price Target | 4.30 (+444.3%) |
| Earnings Date | Aug 11, 2026 |
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in ... [Read more]
Financial Performance
In 2025, Aprea Therapeutics's revenue was $285,759, a decrease of -80.98% compared to the previous year's $1.50 million. Losses were -$12.60 million, -2.77% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for APRE stock is "Strong Buy." The 12-month stock price target is $4.3, which is an increase of 444.30% from the latest price.
News
Aprea Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, a reverse stock split, and executive compensation, with all proposals approved by stockholders. No questions were raised, and final voting results will be filed in a Form 8-K.
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohort...
Aprea Therapeutics price target lowered to $6 from $7 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Aprea Therapeutics (APRE) to $6 from $7 and keeps an Outperform rating on the shares. The firm notes the company…
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
As of March 31 the Company reported cash and cash equivalents of $46.5M compared to $14.6M as of December 31, 2025. The Company believes that its cash will be sufficient…
Aprea Therapeutics Earnings release: Q1 2026
Aprea Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Aprea Therapeutics Quarterly report: Q1 2026
Aprea Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and...
Aprea Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Aprea Therapeutics (APRE) with an Outperform rating and $5 price target The firm cites the potential of the company’s WEE1 inhibitor APR-1051 and the stock’s “sizable...
Aprea Therapeutics Proxy statement: Proxy filing
Aprea Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Aprea Therapeutics Proxy statement: Proxy filing
Aprea Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Aprea Therapeutics files to sell 74.35M shares of common stock for holders
17:02 EDT Aprea Therapeutics (APRE) files to sell 74.35M shares of common stock for holders
Aprea Therapeutics Registration statement: Registration filing
Aprea Therapeutics filed a registration statement on April 22, 2026, providing details about a securities offering with the SEC.
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...
Aprea Therapeutics Proxy statement: Proxy filing
Aprea Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...
Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aprea Therapeutics (APRE) to $1.20 from $4 and keeps a Buy rating on the shares. The firm cites the “significant dilution” from…
Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial
Aprea Therapeutics (APRE) announced the confirmation of a partial response, or PR, in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor. The confirmed PR ...
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- ...
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emer...
Aprea Therapeutics Registration statement: Registration Filing
Aprea Therapeutics filed a registration statement on March 17, 2026, providing details about a securities offering with the SEC.
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
Reports revenue $3,337 vs. $205,817 last year. “We enter 2026 with strong momentum following a year of meaningful execution across our portfolio,” said Oren Gilad, Ph.D., President and Chief Executive...
Aprea Therapeutics sees cash runway into 1Q27
As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million compared to $22.8 million as of December 31, 2024. The Company believes its cash and cash…
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery a...
Aprea Therapeutics Annual report: Q4 2025
Aprea Therapeutics has published its Q4 2025 annual report on March 16, 2026.
Aprea Therapeutics Earnings release: Q4 2025
Aprea Therapeutics released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.